undamentalytics Newsletter
Sign in

Adaptive Biotechnologies Corp income statement

In fiscal 2025, Adaptive Biotechnologies Corp reported revenue of $277m, up 54.8% on the year before, operating income of −$57.1m (a -20.6% margin) and net income of −$59.5m, or −$0.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue38568598154185170179277308
Cost of revenue16202223495876727175
Gross profit2336637610512795107206233
Research and development3239711161421421221039488
Selling and marketing172438619596898595101
General and administrative16203050758984737380
Operating income−44−50−78−153−209−200−227−163−57−37
Interest expense—————414121212
Income before tax——−69−146−207−200−225−160−59—
Income tax——0———000—
Net income−43−46−69−146−207−200−225−159−59−64
Diluted EPS−$1.75−$1.83−$0.51−$1.11−$1.48−$1.40−$1.56−$1.08−$0.39−$0.41
Diluted shares (average)24m25m138m131m140m143m144m147m152m155m
EBITDA−40−45−72−146−197−179−207−145−41−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADPT vs VCELADPT vs VIRADPT vs ARVNADPT vs IOVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adaptive Biotechnologies Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adaptive Biotechnologies Corp.